Protein domains

Eureka Therapeutics Announces New GPRC5D License Agreement with Sanofi to Target Multiple Myeloma

Retrieved on: 
Tuesday, July 6, 2021

The GPRC5D binding domain was discovered using Eurekas proprietary E-ALPHA antibody discovery platform and developed under a collaboration agreement between Eureka and MSK.

Key Points: 
  • The GPRC5D binding domain was discovered using Eurekas proprietary E-ALPHA antibody discovery platform and developed under a collaboration agreement between Eureka and MSK.
  • GPRC5D is a novel target that has emerged as a promising option for the treatment of multiple myeloma, particularly for patients who have relapsed from other therapies, said Dr. Eric L. Smith, myeloma physician-scientist and an inventor on the patents.
  • We are delighted to contribute technology for the development of next generation therapies against multiple myeloma, said Dr. Cheng Liu, President and Chief Executive Officer of Eureka Therapeutics.
  • Under the terms of the agreement, Sanofi has exclusive rights to the GPRC5D binder for non-CAR use.

Precision BioSciences and SpringWorks Therapeutics Dose First Patient in Expanded Phase 1/2a Clinical Trial Evaluating PBCAR269A with Nirogacestat in Patients with Relapsed/Refractory Multiple Myeloma

Retrieved on: 
Monday, June 28, 2021

In the study, Precisions investigational allogeneic BCMA-targeted CAR T cell therapy will be combined with nirogacestat, SpringWorks investigational gamma secretase inhibitor (GSI), in patients with relapsed/refractory (R/R) multiple myeloma.

Key Points: 
  • In the study, Precisions investigational allogeneic BCMA-targeted CAR T cell therapy will be combined with nirogacestat, SpringWorks investigational gamma secretase inhibitor (GSI), in patients with relapsed/refractory (R/R) multiple myeloma.
  • We are pleased to begin dosing patients in the combination arm of our ongoing Phase 1/2a study evaluating PBCAR269A, our first-generation allogeneic CAR T candidate targeting BCMA in patients with R/R multiple myeloma.
  • In September 2020, Precision and SpringWorks entered into a clinical collaboration in which Precision is sponsoring the expanded Phase 1/2a study of PBCAR269A to include nirogacestat and evaluate the safety and preliminary clinical activity of the combination therapy.
  • Simultaneously, Precision continues to enroll patients in the highest dose cohort (Dose Level 3 at 6.0 106 cells/kg) in its monotherapy study with PBCAR269A.

Bristol Myers Squibb Receives Positive CHMP Opinion for Anti-BCMA CAR T Cell Therapy Abecma (idecabtagene vicleucel) for Relapsed and Refractory Multiple Myeloma

Retrieved on: 
Friday, June 25, 2021

As the first CAR T cell therapy for relapsed and refractory multiple myeloma to receive a positive CHMP opinion, Abecma represents a potential new treatment approach for patients in Europe battling this incurable blood cancer, said Noah Berkowitz, M.D., Ph.D., senior vice president, Cellular Therapy Development, Bristol Myers Squibb.

Key Points: 
  • As the first CAR T cell therapy for relapsed and refractory multiple myeloma to receive a positive CHMP opinion, Abecma represents a potential new treatment approach for patients in Europe battling this incurable blood cancer, said Noah Berkowitz, M.D., Ph.D., senior vice president, Cellular Therapy Development, Bristol Myers Squibb.
  • The EMA previously granted Abecma access to the PRIority MEdicines (PRIME) scheme for the treatment of relapsed and refractory multiple myeloma.
  • Abecma recognizes and binds to BCMA on the surface of multiple myeloma cells leading to CAR T cell proliferation, cytokine secretion, and subsequent cytolytic killing of BCMA-expressing cells.
  • ABECMA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the ABECMA REMS.

Innovent Biologics and IASO Biotherapeutics to Present Updated Data from its Anti-BCMA CAR-T Therapy in Relapsed/Refractory Multiple Myeloma at European Hematology Association (EHA) Congress

Retrieved on: 
Tuesday, June 8, 2021

Among them, eight patients had extramedullary multiple myeloma (EMM) and one patient had complication with plasma cell leukemia.

Key Points: 
  • Among them, eight patients had extramedullary multiple myeloma (EMM) and one patient had complication with plasma cell leukemia.
  • All patients previously treated with murine BCMA CAR-T or patients with extramedullary multiple myeloma (EMM) benefited from IBI326.
  • The updated data reinforce the advantages and uniqueness of CT103A in the treatment of patients with relapsed/refractory multiple myeloma.
  • In February 2021, IBI326 was granted breakthrough therapy designation by the NMPA for the treatment of relapsed/refractory multiple myeloma.

SpringWorks Therapeutics Announces Clinical Collaboration with Seagen to Evaluate Nirogacestat in Combination with SEA-BCMA in Patients with Relapsed or Refractory Multiple Myeloma

Retrieved on: 
Monday, June 7, 2021

Gamma secretase inhibition prevents the cleavage and shedding of BCMA from the surface of myeloma cells.

Key Points: 
  • Gamma secretase inhibition prevents the cleavage and shedding of BCMA from the surface of myeloma cells.
  • Our goal is to meaningfully improve clinical outcomes for patients with multiple myeloma and we look forward to generating clinical data using nirogacestat in combination with BCMA-directed therapies across modalities.
  • Seagen and SpringWorks will also form a joint development committee to manage the clinical study, which is expected to commence in the second half of 2021.
  • Nirogacestats ability to enhance the activity of BCMA-directed therapies has been observed in preclinical models of multiple myeloma.

Clinical Trial Results of the BCMA CAR-T Co-developed by IASO Biotherapeutics and Innovent Commented in American Society of Hematology’s Medical Journal, Blood

Retrieved on: 
Friday, June 4, 2021

The article is titled A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.

Key Points: 
  • The article is titled A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.
  • The clinical study published in Blood was conducted in the Department of Hematology, at Tongji Medical College of Huazhong University of Science and Technology (HUST) in China (ChiCTR1800018137).
  • This study enrolled four patients who had previously been treated with a murine BCMA CAR For the 4 murine BCMA CARexposed patients.
  • Immunogenicity: Anti-drug antibodies (ADA) were tested in all 18 subjects and two samples of one subject were validated as positive for ADA.

Janssen’s Updated Phase 1 Results for Teclistamab Suggest Deep, Durable Responses in Patients with Heavily Pretreated Multiple Myeloma

Retrieved on: 
Monday, May 24, 2021

Dose Escalation Study of Teclistamab, a Humanized BCMA CD3 DuoBody Antibody, in Participants With Relapsed or Refractory Multiple Myeloma.

Key Points: 
  • Dose Escalation Study of Teclistamab, a Humanized BCMA CD3 DuoBody Antibody, in Participants With Relapsed or Refractory Multiple Myeloma.
  • Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) CD3bispecific antibody, in relapsed/refractory multiple myeloma (MM).
  • Teclistamab and Talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and/or refractory multiple myeloma.
  • A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma.

Janssen Presents Updated Data on First-in-Class Talquetamab at ASCO Suggesting Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma

Retrieved on: 
Monday, May 24, 2021

Patients in this study had progressed, had relapsed after, or were refractory to numerous multiple myeloma therapies.

Key Points: 
  • Patients in this study had progressed, had relapsed after, or were refractory to numerous multiple myeloma therapies.
  • As of April 18, 2021, 184 patients with relapsed or refractory multiple myeloma had received talquetamab.
  • Janssen Pharmaceutica NV, Janssen Research & Development, LLC, and Janssen-Cilag Limited are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
  • Teclistamab and Talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and/or refractory multiple myeloma.

Janssen's Updated Phase 1 Results for Teclistamab Suggest Deep, Durable Responses in Patients with Heavily Pretreated Multiple Myeloma

Retrieved on: 
Monday, May 24, 2021

With this latest follow-up data, we present further evidence of promising clinical activity in heavily pretreated patients, who are in urgent need of new therapeutic options."

Key Points: 
  • With this latest follow-up data, we present further evidence of promising clinical activity in heavily pretreated patients, who are in urgent need of new therapeutic options."
  • In2020, the European Commission and the U.S. Food and Drug Administration each granted teclistamab orphan drug designation for the treatment of multiple myeloma.
  • Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) CD3bispecific antibody, in relapsed/refractory multiple myeloma (MM).
  • Teclistamab and Talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and/or refractory multiple myeloma.

Harpoon Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 6, 2021

Key findings include:\nFLT3-targeting TriTACs\xc2\xa0are T cell engagers with a potential role in the treatment of acute myeloid leukemia.

Key Points: 
  • Key findings include:\nFLT3-targeting TriTACs\xc2\xa0are T cell engagers with a potential role in the treatment of acute myeloid leukemia.
  • HPN217 targets B-cell maturation antigen (BCMA).\nHarpoon ended the first quarter of 2021 with $239.4 million in cash, cash equivalents, and marketable securities compared to $150.0 million as of December 31, 2020.
  • These forward-looking statements are based on Harpoon Therapeutics\xe2\x80\x99 expectations and assumptions as of the date of this press release.
  • Except as required by law, Harpoon Therapeutics assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.\n'